Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
41.15
+0.95 (2.36%)
Aug 13, 2025, 4:00 PM - Market closed
AAPG Revenue
In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M CNY with 341.77% growth. Ascentage Pharma Group International had revenue of 156.90M in the half year ending December 31, 2024, with 37.70% growth.
Revenue (ttm)
980.65M CNY
Revenue Growth
+341.77%
P/S Ratio
28.56
Revenue / Employee
1,729,541 CNY
Employees
567
Market Cap
3.84B undefined
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AAPG News
- 6 days ago - Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 - GlobeNewsWire
- 12 days ago - Ascentage Pharma to Participate in Evercore China Biotech Summit - GlobeNewsWire
- 27 days ago - Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma Announces Pricing of Top-Up Placement - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma Announces Proposed Top-Up Placement - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance - GlobeNewsWire
- 2 months ago - EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - GlobeNewsWire